Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
JAMA
    April 2018
  1. ZHAO Q, Zhu Y, Xu Z, Cheng Z, et al
    Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
    JAMA. 2018;319:1677-1686.
    >> Share

  2. ALEXANDER JH
    Ticagrelor Following Coronary Artery Bypass Grafting: For Better Vein Graft Patency or Better Patient Outcomes?
    JAMA. 2018;319:1661-1662.
    >> Share

  3. NAVARESE EP, Robinson JG, Kowalewski M, Kolodziejczak M, et al
    Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
    JAMA. 2018;319:1566-1579.
    >> Share

  4. ABBASI J
    Using Heart Pump Data to Manage Cardiogenic Shock.
    JAMA. 2018;319:1427.
    >> Share

  5. YU K, Qiu G, Chan KH, Lam KH, et al
    Association of Solid Fuel Use With Risk of Cardiovascular and All-Cause Mortality in Rural China.
    JAMA. 2018;319:1351-1361.
    >> Share

    March 2018
  6. GUPTA A, Das SR, Pandey A
    beta-Blockers in Myocardial Infarction: Issues With Standard Admission Order Sets.
    JAMA. 2018;319:1269-1270.
    >> Share

  7. BERWANGER O, Santucci EV, de Barros E Silva PGM, Jesuino IA, et al
    Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
    JAMA. 2018 Mar 11. pii: 2675023. doi: 10.1001/jama.2018.2444.
    >> Share

  8. NICHOLLS SJ, Psaltis PJ
    Lipid Lowering in Acute Coronary Syndrome: Is Treatment Early Enough?
    JAMA. 2018 Mar 11. pii: 2675022. doi: 10.1001/jama.2018.2426.
    >> Share

  9. ABBASI J
    Do All Patients Need beta-Blockers After a Heart Attack?
    JAMA. 2018;319:853-855.
    >> Share

    February 2018
  10. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.
    JAMA. 2018;319:567-578.
    >> Share

    January 2018
  11. WADHERA RK, Yeh RW, Joynt Maddox KE
    The Rise and Fall of Mandatory Cardiac Bundled Payments.
    JAMA. 2018;319:335-336.
    >> Share

  12. KENNEDY AB, Lavie CJ, Blair SN
    Fitness or Fatness: Which Is More Important?
    JAMA. 2018;319:231-232.
    >> Share

    December 2017
  13. GREENLAND P
    Cardiovascular Guideline Skepticism vs Lifestyle Realism?
    JAMA. 2017 Dec 14. pii: 2666625. doi: 10.1001/jama.2017.19675.
    >> Share

    November 2017
  14. SLOMSKI A
    Evolocumab Reduces Cardiovascular Risk Regardless of Diabetes Status.
    JAMA. 2017;318:1968.
    >> Share

  15. EMDIN CA, Khera AV, Kathiresan S
    Mendelian Randomization.
    JAMA. 2017;318:1925-1926.
    >> Share

  16. IRONY TZ
    The "Utility" in Composite Outcome Measures: Measuring What Is Important to Patients.
    JAMA. 2017;318:1820-1821.
    >> Share

  17. CHAPMAN AR, Lee KK, McAllister DA, Cullen L, et al
    Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.
    JAMA. 2017 Nov 11. doi: 10.1001/jama.2017.17488.
    >> Share

    October 2017
  18. ABBASI J
    Could a New Method to Detect Coronary Inflammation Prevent Heart Attacks?
    JAMA. 2017;318:1527-1528.
    >> Share

    September 2017
  19. WADHERA RK, Bhatt DL
    Taking the "Public" Out of Public Reporting of Percutaneous Coronary Intervention.
    JAMA. 2017 Sep 28. doi: 10.1001/jama.2017.12087.
    >> Share

  20. LICHTMAN JH, Jones MR, Leifheit EC, Sheffet AJ, et al
    Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014.
    JAMA. 2017;318:1035-1046.
    >> Share

  21. BARNARD ND, Willett WC, Ding EL
    The Misuse of Meta-analysis in Nutrition Research.
    JAMA. 2017 Sep 18. doi: 10.1001/jama.2017.12083.
    >> Share

  22. DEVEREAUX PJ, Biccard BM, Chan MTV
    High-Sensitivity Troponin Levels, Ischemia, and Mortality-Reply.
    JAMA. 2017;318:865.
    >> Share

  23. SMILOWITZ NR
    High-Sensitivity Troponin Levels, Ischemia, and Mortality.
    JAMA. 2017;318:864-865.
    >> Share

    August 2017
  24. FERENCE BA, Kastelein JJP, Ginsberg HN, Chapman MJ, et al
    Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    JAMA. 2017 Aug 28. doi: 10.1001/jama.2017.11467.
    >> Share

  25. FELKER GM, Anstrom KJ, Adams KF, Ezekowitz JA, et al
    Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    JAMA. 2017;318:713-720.
    >> Share

  26. CHOLLEY B, Caruba T, Grosjean S, Amour J, et al
    Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.
    JAMA. 2017;318:548-556.
    >> Share

  27. KRUMHOLZ HM
    Treatment of Cholesterol in 2017.
    JAMA. 2017;318:417-418.
    >> Share

    July 2017
  28. LARSSON SC, Burgess S, Michaelsson K
    Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction.
    JAMA. 2017;318:371-380.
    >> Share

  29. IOANNIDIS JPA
    Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    JAMA. 2017 Jul 24. doi: 10.1001/jama.2017.6765.
    >> Share

  30. DHARMARAJAN K, Wang Y, Lin Z, Normand ST, et al
    Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge.
    JAMA. 2017;318:270-278.
    >> Share

  31. GROSSMAN DC, Bibbins-Domingo K, Curry SJ, Barry MJ, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2017;318:167-174.
    >> Share

  32. PATNODE CD, Evans CV, Senger CA, Redmond N, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Tas
    JAMA. 2017;318:175-193.
    >> Share

  33. JIN J
    Counseling on Healthy Living to Prevent Cardiovascular Disease in Adults Without Risk Factors.
    JAMA. 2017;318:210.
    >> Share

  34. YU J, Zhou Z, McEvoy RD, Anderson CS, et al
    Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis.
    JAMA. 2017;318:156-166.
    >> Share

  35. GOTTLIEB DJ
    Does Obstructive Sleep Apnea Treatment Reduce Cardiovascular Risk?: It Is Far Too Soon to Say.
    JAMA. 2017;318:128-130.
    >> Share

  36. GREENLAND P, Fuster V
    Cardiovascular Risk Factor Control for All.
    JAMA. 2017;318:130-131.
    >> Share

    June 2017
  37. BUDOFF MJ, Ellenberg SS, Snyder PJ
    Changes in Coronary Artery Plaque With Testosterone Therapy-Reply.
    JAMA. 2017;317:2451.
    >> Share

  38. DHINDSA S, Wilson MF, Dandona P
    Changes in Coronary Artery Plaque With Testosterone Therapy.
    JAMA. 2017;317:2450.
    >> Share

  39. NAVATHE AS, Song Z, Emanuel EJ
    The Next Generation of Episode-Based Payments.
    JAMA. 2017;317:2371-2372.
    >> Share

  40. CHILDERS CP, Maggard-Gibbons M, Shekelle PG
    Antiplatelet Therapy in Patients With Coronary Stents Undergoing Elective Noncardiac Surgery: Continue, Stop, or Something in Between?
    JAMA. 2017 Jun 19. doi: 10.1001/jama.2017.7845.
    >> Share

    May 2017
  41. SLOMSKI A
    Redefining Acute Coronary Syndrome Therapy.
    JAMA. 2017;317:2054.
    >> Share

  42. ROTH GA, Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, et al
    Trends and Patterns of Geographic Variation in Cardiovascular Mortality Among US Counties, 1980-2014.
    JAMA. 2017;317:1976-1992.
    >> Share

  43. MENSAH GA, Goff DC, Gibbons GH
    Cardiovascular Mortality Differences-Place Matters.
    JAMA. 2017;317:1955-1957.
    >> Share

    April 2017
  44. NICHOLLS SJ, Somaratne R, Nissen SE
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis-Reply.
    JAMA. 2017;317:1691.
    >> Share

  45. ALKHALIL M, Choudhury RP
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    JAMA. 2017;317:1690-1691.
    >> Share

  46. MURRAY SW
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    JAMA. 2017;317:1690.
    >> Share

  47. DEVEREAUX PJ, Biccard BM, Sigamani A, Xavier D, et al
    Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery.
    JAMA. 2017;317:1642-1651.
    >> Share

  48. SCHWARTZ MLB, Williams MS, Murray MF
    Adding Protective Genetic Variants to Clinical Reporting of Genomic Screening Results: Restoring Balance.
    JAMA. 2017;317:1527-1528.
    >> Share

    March 2017
  49. KHERA AV, Won HH, Peloso GM, O'Dushlaine C, et al
    Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease.
    JAMA. 2017;317:937-946.
    >> Share

    February 2017
  50. BUDOFF MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, et al
    Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.
    JAMA. 2017;317:708-716.
    >> Share

  51. AGORITSAS T, Merglen A, Shah ND, O'Donnell M, et al
    Adjusted Analyses in Studies Addressing Therapy and Harm: Users' Guides to the Medical Literature.
    JAMA. 2017;317:748-759.
    >> Share

  52. BILECEN S, de Groot JA, Kalkman CJ, Spanjersberg AJ, et al
    Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial.
    JAMA. 2017;317:738-747.
    >> Share

  53. EMDIN CA, Khera AV, Natarajan P, Klarin D, et al
    Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease.
    JAMA. 2017;317:626-634.
    >> Share

    January 2017
  54. SILVERMAN MG, Im K, Sabatine MS
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply.
    JAMA. 2017;317:440.
    >> Share

  55. ZAFAR K, Inayat M
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439-440.
    >> Share

  56. NAVARESE EP, Kolodziejczak M, De Servi S
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439.
    >> Share

  57. BRAGG F, Holmes MV, Iona A, Guo Y, et al
    Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China.
    JAMA. 2017;317:280-289.
    >> Share

  58. GREENWOOD JP, Brown JM, Berry C
    Alternatives in the Evaluation of Suspected Coronary Heart Disease-Reply.
    JAMA. 2017;317:212-213.
    >> Share

  59. SCHWITTER J
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211-212.
    >> Share

  60. BITTENCOURT MS, Fernandes JL
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211.
    >> Share

  61. FOROUZANFAR MH, Liu P, Roth GA, Ng M, et al
    Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015.
    JAMA. 2017;317:165-182.
    >> Share

    December 2016
  62. SLOMSKI A
    Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety.
    JAMA. 2016;316:2589.
    >> Share

  63. DESAI NR, Ross JS, Kwon JY, Herrin J, et al
    Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions.
    JAMA. 2016;316:2647-2656.
    >> Share

  64. MORA S, Manson JE
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply.
    JAMA. 2016;316:2276-2277.
    >> Share

  65. STOVITZ SD, Satin DJ, Shrier I
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease.
    JAMA. 2016;316:2276.
    >> Share

    November 2016
  66. NICHOLLS SJ, Puri R, Anderson T, Ballantyne CM, et al
    Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.16951.
    >> Share

  67. NAVAR AM, Peterson ED, Wojdyla D, Sanchez RJ, et al
    Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence.
    JAMA. 2016;316:2041-2043.
    >> Share

  68. KAVOUSI M, Desai CS, Ayers C, Blumenthal RS, et al
    Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.17020.
    >> Share

  69. RODRIGUEZ F, Harrington RA
    Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
    JAMA. 2016;316:1967-1968.
    >> Share

  70. BIBBINS-DOMINGO K, Grossman DC, Curry SJ, Davidson KW, et al
    Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2016;316:1997-2007.
    >> Share

  71. CHOU R, Dana T, Blazina I, Daeges M, et al
    Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:2008-2024.
    >> Share

  72. SONG Z, Blumenthal DM
    Expanding Payment Reform in Medicare: The Cardiology Episode-Based Payment Model.
    JAMA. 2016;316:1973-1974.
    >> Share

  73. ABBASI J
    Do Apollo Astronaut Deaths Shine a Light on Deep Space Radiation and Cardiovascular Disease?
    JAMA. 2016 Nov 9. doi: 10.1001/jama.2016.12601.
    >> Share

  74. LEGATO MJ, Johnson PA, Manson JE
    Consideration of Sex Differences in Medicine to Improve Health Care and Patient Outcomes.
    JAMA. 2016;316:1865-1866.
    >> Share

    October 2016
  75. HAMPTON T
    Reservoir of Genetic Data Related to Cardiovascular Disease.
    JAMA. 2016;316:1349.
    >> Share

  76. LOTTA LA, Sharp SJ, Burgess S, Perry JR, et al
    Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
    JAMA. 2016;316:1383-1391.
    >> Share

    September 2016
  77. SILVERMAN MG, Ference BA, Im K, Wiviott SD, et al
    Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    JAMA. 2016;316:1289-97.
    >> Share

  78. MILLS K, He J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112-3.
    >> Share

  79. ALMIRALL J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    >> Share

  80. HURSITOGLU M
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    >> Share

  81. HEMKENS LG, Ewald H, Briel M
    Colchicine and Prevention of Cardiovascular Events.
    JAMA. 2016;316:1106-7.
    >> Share

    August 2016
  82. HALL M, Dondo TB, Yan AT, Goodman SG, et al
    Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.10766.
    >> Share

  83. BOHULA EA, Antman EM
    Management of Non-ST-Elevation Myocardial Infarction: The Bright Gleam of Progress, But Much Work Remains.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.11940.
    >> Share

  84. GREENWOOD JP, Ripley DP, Berry C, McCann GP, et al
    Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.
    JAMA. 2016 Aug 29. doi: 10.1001/jama.2016.12680.
    >> Share

  85. KAZI DS, Moran AE, Coxson PG, Penko J, et al
    Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    JAMA. 2016;316:743-53.
    >> Share

  86. LIVINGSTON EH
    JAMA PATIENT PAGE. Screening for Lipid Disorders in Children and Adolescents.
    JAMA. 2016;316:678.
    >> Share

  87. LOZANO P, Henrikson NB, Dunn J, Morrison CC, et al
    Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:645-55.
    >> Share

  88. LOZANO P, Henrikson NB, Morrison CC, Dunn J, et al
    Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:634-44.
    >> Share

    July 2016
  89. NUTI SV, Qin L, Krumholz HM
    Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals--Reply.
    JAMA. 2016;316:346.
    >> Share

  90. RADOMSKI TR, Fine MJ, Gellad WF
    Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals.
    JAMA. 2016;316:345-6.
    >> Share

    June 2016
  91. CHOBANIAN AV
    SPRINT Results in Older Patients: How Low to Go?
    JAMA. 2016;315:2669-70.
    >> Share

  92. GANZ P, Heidecker B, Hveem K, Jonasson C, et al
    Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.
    JAMA. 2016;315:2532-41.
    >> Share

  93. SABATINE MS
    Using Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction.
    JAMA. 2016;315:2525-6.
    >> Share

  94. MORA S, Ames JM, Manson JE
    Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
    JAMA. 2016 Jun 20. doi: 10.1001/jama.2016.8362.
    >> Share

  95. HONG SJ, Kim BK, Hong MK
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation--Reply.
    JAMA. 2016;315:2469-70.
    >> Share

  96. STEINVIL A, Waksman R, Garcia-Garcia HM
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2469.
    >> Share

  97. TUNCEZ A, Altunkeser BB
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2468-9.
    >> Share

  98. HOFFER EK
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2468.
    >> Share

  99. MANSON JE, Shufelt CL, Robins JM
    The Potential for Postrandomization Confounding in Randomized Clinical Trials.
    JAMA. 2016;315:2273-4.
    >> Share

    May 2016
  100. MILLS KT, Chen J, Yang W, Appel LJ, et al
    Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease.
    JAMA. 2016;315:2200-10.
    >> Share

  101. POWE NR, Bibbins-Domingo K
    Dietary Salt, Kidney Disease, and Cardiovascular Health.
    JAMA. 2016;315:2173-4.
    >> Share

  102. WILLIAMSON JD, Supiano MA, Applegate WB, Berlowitz DR, et al
    Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial.
    JAMA. 2016 May 19. doi: 10.1001/jama.2016.7050.
    >> Share

    April 2016
  103. PENCINA MJ, Peterson ED
    Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
    JAMA. 2016;315:1713-4.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016